View Cart (0 items)
Pharmaceutical

Risk-based inspections: What’s the FDA looking for?

April 11, 2005
/ Print / Reprints /
| Share More
/ Text Size+

The final of three keynote sessions at INTERPHEX will be held at 9:00 a.m. Thursday, April 28 in Hall 1A. An FDA inspection is not something most people look forward to. John M. Taylor III, Associate Commissioner for Regulatory Affairs, FDA, will describe what constitutes a high risk that is likely to cause an FDA inspection, and what happens when you get inspected.

You must login or register in order to post a comment.